347 related articles for article (PubMed ID: 22339953)
21. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lee KH; Lee JH; Choi SJ; Lee JH; Seol M; Lee YS; Kim WK; Lee JS; Seo EJ; Jang S; Park CJ; Chi HS
Leukemia; 2005 Sep; 19(9):1509-16. PubMed ID: 16034462
[TBL] [Abstract][Full Text] [Related]
22. Prolonged survival with imatinib mesylate combined with chemotherapy and allogeneic stem cell transplantation in de novo Ph+ acute myeloid leukemia.
Sun J; Wang Z; Luo Y; Tan Y; Allan DS; Huang H
Acta Haematol; 2012; 127(3):143-8. PubMed ID: 22248505
[TBL] [Abstract][Full Text] [Related]
23. [Application of imatinib plus Hyper-CVAD chemotherapy regimen in patients with Ph chromosome positive acute lymphocytic leukemia].
Guo Z; Chen HR; Liu XD; Yang K; Chen P; Liu B; Liu D; Wang BR; Yao YS; He XP
Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1384-7. PubMed ID: 21756808
[TBL] [Abstract][Full Text] [Related]
24. Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lim SN; Joo YD; Lee KH; Kim DY; Lee JH; Lee JH; Chi HS; Yun SC; Lee WS; Lee SM; Park S; Kim I; Sohn SK; Moon JH; Ryoo HM; Bae SH; Hyun MS; Kim MK; Kim HJ; Yang DH; Eom HS; Lee GW; Jung CW; Won JH; Kim H; Lee JH; Shin HJ; Jang DY
Am J Hematol; 2015 Nov; 90(11):1013-20. PubMed ID: 26228525
[TBL] [Abstract][Full Text] [Related]
25. Prediction of risk of disease recurrence by genome-wide cDNA microarray analysis in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy.
Zembutsu H; Yanada M; Hishida A; Katagiri T; Tsuruo T; Sugiura I; Takeuchi J; Usui N; Naoe T; Nakamura Y; Ohno R
Int J Oncol; 2007 Aug; 31(2):313-22. PubMed ID: 17611687
[TBL] [Abstract][Full Text] [Related]
26. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Sancho JM; Ribera JM; Xicoy B; Morgades M; Oriol A; Tormo M; del Potro E; Debén G; Abella E; Bethencourt C; Ortín X; Brunet S; Ortega-Rivas F; Novo A; López R; Hernández-Rivas JM; Sanz MA; Feliu E;
Eur J Haematol; 2007 Feb; 78(2):102-10. PubMed ID: 17087744
[TBL] [Abstract][Full Text] [Related]
27. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Faderl S; Kantarjian HM; Thomas DA; Cortes J; Giles F; Pierce S; Albitar M; Estrov Z
Leuk Lymphoma; 2000 Jan; 36(3-4):263-73. PubMed ID: 10674898
[TBL] [Abstract][Full Text] [Related]
28. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
[TBL] [Abstract][Full Text] [Related]
29. [Efficacies of hematopoietic stem cell transplantation plus imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia: a comparative study].
Chen J; Wu DP; Chen F; Zhao Y; Sun AN; Qiu HY
Zhonghua Yi Xue Za Zhi; 2013 Feb; 93(8):583-7. PubMed ID: 23663336
[TBL] [Abstract][Full Text] [Related]
30. [Successful induction and long-term molecular remission with imatinib mesylate and chemotherapy in a case of Ph-positive acute lymphoblastic leukemia].
Hirayama Y; Sakamaki S; Takayanagi N; Tsuji Y; Sagawa T; Chiba H; Maeda M; Matsunaga T; Kato J; Niitsu Y
Rinsho Ketsueki; 2003 May; 44(5):334-8. PubMed ID: 12822409
[TBL] [Abstract][Full Text] [Related]
31. Aberrant expression of CD13 identifies a subgroup of standard-risk adult acute lymphoblastic leukemia with inferior survival.
Dalal BI; Al Mugairi A; Pi S; Lee SY; Khare NS; Pal J; Bryant A; Vakil AP; Lau S; Abou Mourad YR
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):239-44. PubMed ID: 24411984
[TBL] [Abstract][Full Text] [Related]
32. Expression of myeloid antigens by blast cells in acute lymphoblastic leukemia of adults. The Southwest Oncology Group experience.
Boldt DH; Kopecky KJ; Head D; Gehly G; Radich JP; Appelbaum FR
Leukemia; 1994 Dec; 8(12):2118-26. PubMed ID: 7807999
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
[TBL] [Abstract][Full Text] [Related]
34. Outcome of childhood acute lymphoblastic leukemia with induction failure treated by the Japan Association of Childhood Leukemia study (JACLS) ALL F-protocol.
Suzuki N; Yumura-Yagi K; Yoshida M; Hara J; Nishimura S; Kudoh T; Tawa A; Usami I; Tanizawa A; Hori H; Ito Y; Miyaji R; Oda M; Kato K; Hamamoto K; Osugi Y; Hashii Y; Nakahata T; Horibe K;
Pediatr Blood Cancer; 2010 Jan; 54(1):71-8. PubMed ID: 19813250
[TBL] [Abstract][Full Text] [Related]
35. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study.
Takeuchi J; Kyo T; Naito K; Sao H; Takahashi M; Miyawaki S; Kuriyama K; Ohtake S; Yagasaki F; Murakami H; Asou N; Ino T; Okamoto T; Usui N; Nishimura M; Shinagawa K; Fukushima T; Taguchi H; Morii T; Mizuta S; Akiyama H; Nakamura Y; Ohshima T; Ohno R
Leukemia; 2002 Jul; 16(7):1259-66. PubMed ID: 12094249
[TBL] [Abstract][Full Text] [Related]
36. Favorable outcome of unrelated cord blood transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Onishi Y; Sasaki O; Ichikawa S; Inokura K; Katsuoka Y; Ohtsuka Ohba R; Okitsu Y; Kohata K; Ohguchi H; Fukuhara N; Yokoyama H; Yamada MF; Yamamoto J; Ishizawa K; Kameoka J; Harigae H
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1093-7. PubMed ID: 21277378
[TBL] [Abstract][Full Text] [Related]
37. Philadelphia chromosome-positive mixed phenotype acute leukemia in the imatinib era.
Shimizu H; Yokohama A; Hatsumi N; Takada S; Handa H; Sakura T; Nojima Y
Eur J Haematol; 2014 Oct; 93(4):297-301. PubMed ID: 24750307
[TBL] [Abstract][Full Text] [Related]
38. Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy.
Yanada M; Takeuchi J; Sugiura I; Akiyama H; Usui N; Yagasaki F; Nishii K; Ueda Y; Takeuchi M; Miyawaki S; Maruta A; Narimatsu H; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
Haematologica; 2008 Feb; 93(2):287-90. PubMed ID: 18223280
[TBL] [Abstract][Full Text] [Related]
39. [Comparison of the efficiency of CHOP-based regimen with or without high dose consolidation treatment combined with hematopoietic stem cell transplantation in 63 lymphoblastic lymphoma patients].
Qin Y; Shi YK; He XH; Han XH; Zhou SY; Liu P; Yang JL; Yang S; Zhang CG; Dong M; Zhou LQ; Wang JW; Feng FY; Sun Y
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):469-73. PubMed ID: 19950562
[TBL] [Abstract][Full Text] [Related]
40. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]